ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

UPC vs CNSP // RSI-14 & 200D SMA MOMENTUM

Universe Pharmaceuticals Inc. (Class A) (NASDAQ) VS. CNS Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: UPC 2 — CNSP 1
▲ RSI-14 & 200D SMA MOMENTUM LEADER: CNSP
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UPC VS. CNSP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC UPC CNSP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 35.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) — -35.00% — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -16.30% — — TIE /operating-margins <GO>
Net Profit Margin -20.60% — — TIE /net-margins <GO>
Revenue Growth (YoY) -22.40% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 1/9 +1.00 UPC /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 22.2 48.9 -26.62 CNSP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $7.7M $7.0M $766.4K UPC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR UPC REV CNSP REV UPC GROSS % CNSP GROSS % UPC FCF CNSP FCF
FY 2025 $17.86B $0 35.3% — -$5.32B -$13.8M
FY 2024 $23.02B $0 26.4% — -$9.72B -$17.1M
FY 2023 $32.31B $0 — — $1.12B -$14.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UPC // BETA —
CNSP // BETA —